| Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma (NCT04446663) | First People's Hospital of Foshan | 2020-07-15 |
| IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. (NCT03854838) | Sun Yat-sen University | 2019-05-01 |
| Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma (NCT03837808) | Sun Yat-sen University | 2019-04-11 |
| GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03840421) | Sun Yat-sen University | 2019-04-03 |
| PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT03619824) | Sun Yat-sen University | 2019-01-01 |
| Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT03700476) | Sun Yat-sen University | 2018-12-21 |
| PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03427827) | Sun Yat-sen University | 2018-07-02 |
| Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma (NCT03093649) | Sun Yat-sen University | 2017-07-01 |
| Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma (NCT03180476) | Sichuan Cancer Hospital and Research Institute | 2017-04-01 |
| A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery (NCT03010813) | Chinese University of Hong Kong | 2016-12-01 |
| A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application (NCT02980315) | The Second Hospital of Nanjing Medical University | 2016-11-01 |
| Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma (NCT02945878) | Zhejiang Cancer Hospital | 2016-10-01 |
| ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (NCT02874651) | Sun Yat-sen University | 2016-10-01 |
| A Trial of Endostar in Patients With Carcinoma of the Head and Neck (NCT02902432) | China International Medical Foundation | 2016-06-01 |
| Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) (NCT02611960) | Merck Sharp & Dohme LLC | 2016-04-18 |
| Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT (NCT02729324) | Yun-fei Xia | 2016-04-01 |
| Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT (NCT02735317) | Yun-fei Xia | 2016-04-01 |
| Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma (NCT02627807) | Sun Yat-sen University | 2015-12-01 |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma (NCT02269943) | Celgene | 2015-02-13 |
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients (NCT02505139) | Sun Yat-sen University | 2014-12-01 |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma (NCT02250599) | Sun Yat-sen University | 2014-08-01 |
| Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma (NCT02211677) | Sun Yat-sen University | 2014-08-01 |
| A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma (NCT02444949) | China Three Gorges University, Yichang, China | 2014-06-01 |
| The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT (NCT01797900) | Chinese Academy of Medical Sciences | 2013-03-01 |
| A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens (NCT01762514) | Sun Yat-sen University | 2013-01-01 |
| Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma (NCT01735409) | Sun Yat-sen University | 2012-11-01 |
| Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma (NCT01528618) | Sun Yat-sen University | 2012-02-21 |
| Environmental and Genetic Determinants of NPC (NCT01257100) | National Cancer Institute (NCI) | 2010-12-08 |
| Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (NCT00747799) | Sun Yat-sen University | 2009-01-01 |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma (NCT02360501) | Sun Yat-sen University | 2008-01-01 |
| Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy (NCT00630149) | Sun Yat-sen University | 2007-11-01 |
| Modified Vaccinia Ankara (MVA) Vaccine Study (NCT01256853) | Chinese University of Hong Kong | 2006-09-01 |
| Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer (NCT00577057) | Hospital Authority, Hong Kong | 2006-09-01 |
| Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma (NCT00363831) | The University of Hong Kong | 2006-07-01 |
| Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families (NCT00393224) | National Cancer Institute (NCI) | 2005-07-05 |
| Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NCT00436800) | Sanofi | 2005-03-01 |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer (NCT00078494) | National Institutes of Health Clinical Center (CC) | 2004-02-01 |
| Intensity Modulated Radiation Therapy for Head and Neck Cancer (NCT00188877) | University Health Network, Toronto | 2003-06-01 |
| Taxotere + Cisplatin in Nasopharyngeal Carcinoma (NCT00436293) | Sanofi | 2002-12-01 |
| Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function (NCT00123864) | Alberta Health services | 2000-01-01 |
| Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) (NCT00563862) | Hospital Authority, Hong Kong | 1999-07-01 |
| Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) (NCT00563927) | Hospital Authority, Hong Kong | 1999-03-01 |
| Family Study of Head and Neck Cancers in Taiwan (NCT00342147) | National Cancer Institute (NCI) | 1995-11-07 |